The UPCI Flow Cytometry Facility moved to its new location at the Hillman Cancer Center Research Pavilion in September 2002. The new laboratory consists of a 200 ft 2 user laboratory (UserLab), and a 1000 ft 2 cell sorting laboratory. The Flow Cytometry Facility of the University of Pittsburgh Cancer Institute provides services to over 50 users within the UPCI and 20 non-UPCI users. These services fall into five categories: 1) Training users to operate the Facility's two user-dedicated analytical flow cytometers; 2) Performing high speed fluorescence activated cell sorting for investigators; 3) Insuring that the instruments in the facility are properly calibrated on a daily basis and advising users concerning the proper settings for their experiments; 4) Advising investigators on experimental design and data analysis and assisting in performance of complex multi-parameter experiments; and 5) Archiving all data produced by the facility. The current instrumentation at the UPCI Flow Cytometry Facility includes a Dako-Cytomation MoFLo high speed cell sorter, equipped with a CytoShield Biocontainment hood, a Dako-Cytomation CyAn 9-color high speed 9 color analyzer, and two Beckman Coulter XL 4-color analyzers. Despite the relocation to the Hillman Cancer Center, the usage of the flow cytometry facility has remained high, with cell sorting exclusive of setup time regularly exceeding 50% of absolute capacity (100 hours/month) and analytical cytometry exceeding 50% of business-hour capacity (160 hours/instrument/month). We anticipate that despite the loss of non-UPCI users resulting from the move, the recruitment of several new UPCI investigators and our continuing emphasis on education and training will more than make up for the loss of non-UPCI investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-19
Application #
7279240
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
19
Fiscal Year
2006
Total Cost
$113,120
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Dongshi; Ni, Hong-Min; Wang, Lei et al. (2018) PUMA induction mediates acetaminophen-induced necrosis and liver injury. Hepatology :
Tahata, Shawn; Singh, Shivendra V; Lin, Yan et al. (2018) Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila) 11:429-438
Moravcikova, Erika; Meyer, E Michael; Corselli, Mirko et al. (2018) Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). Cytometry A 93:894-904
Samuelsson, Laura B; Bovbjerg, Dana H; Roecklein, Kathryn A et al. (2018) Sleep and circadian disruption and incident breast cancer risk: An evidence-based and theoretical review. Neurosci Biobehav Rev 84:35-48
Shiffman, Saul; Mao, Jason M; Kurland, Brenda F et al. (2018) Do non-daily smokers compensate for reduced cigarette consumption when smoking very-low-nicotine-content cigarettes? Psychopharmacology (Berl) 235:3435-3441
Cao, Chunyu; Wu, Hao; Vasilatos, Shauna N et al. (2018) HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. Int J Cancer 143:1388-1401
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Beumer, Jan H; Inker, Lesley A; Levey, Andrew S (2018) Improving Carboplatin Dosing Based on EstimatedĀ GFR. Am J Kidney Dis 71:163-165
Tong, Jingshan; Zheng, Xingnan; Tan, Xiao et al. (2018) Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. Cancer Res 78:4704-4715
Menk, Ashley V; Scharping, Nicole E; Rivadeneira, Dayana B et al. (2018) 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med 215:1091-1100

Showing the most recent 10 out of 1187 publications